Llombart-Cussac A, er al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791-1799. DeMich...
Llombart-Cussac A, er al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791-1799. DeMichele A, Finn RS, et al. Comparative effectiv...
Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CH, Iyer S, Johnston S, Ettl J, Harbeck N (2018) Impact of palbo- ciclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial....
结论:PALOMA-2研究在扩大的人群中证实了P L治疗未经针对晚期疾病系统性治疗的ER /HER2-晚期乳腺癌的显著疗效。临床研究信息:NCT01740427 PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER /HER2– advanced...
Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-neg... Sunil,Verma,Cynthia,... - 《Oncologist》 被引量: 39发表: 2016年 Quality of life with palbociclib plus fulvestrant in previously treated hor...
Different IBCMS methods may lead to different results and could misguide treatment selection; hence, a standardized clinical PAM50 assay and computational approach should be used. Trial number: NCT01740427doi:10.1038/s41523-024-00658-yCheang, Maggie Chon U....
Emulating results in the clinical trial, palbociclib slowed the mediangvalues of the entire population and those with sensitivity to previous endocrine therapy but not those deemed resistant. Further cohort analyses found greater benefit with palbociclib in those with visceral metastases, and longer ...
Llombart-Cussac A, er al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791-1799. ...